Contact us

[ HUMAN VALIDATION / ADC SAFETY ASSESSMENT ]

ADC Safety Assessment

Which normal-tissue risks should your ADC program track first?

[ MULTI-ORGAN-SAFETY ]

ADC Safety Assessment

Which normal-tissue risks should your ADC program track first?

Organ model overview showing brain, lung and organ-specific models.
  1. Define the ADC, its payload and comparators, and the normal-tissue safety questions the study should answer.
  2. Select heart, liver, kidney or bone marrow models, and agree on functional readouts, exposure conditions and controls with the team before execution.
  3. Compare responses across candidates and organs, interpret each result within its model context and document which risks to follow up.
STUDY OUTPUT
An organ-by-organ safety summary that helps prioritize risks for molecule selection and follow-up studies. Methods and deliverables are agreed with the team.
Discuss this application

[ PLAN THE STUDY ]

See how the work connects.

Review the shared study process for model selection, controls, execution and reporting.

View study workflow

[ NEXT STEP ]

Advance Your Next Drug Program with Human-Relevant Evidence.

Tell us what you’re working on. We’ll help you explore the right model, platform or collaboration.

Let’s Talk